Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute leukemia Meeting Abstract
| Authors: | Goldberg, A. D.; Tallman, M. S.; Solh, M. M.; Ungar, D.; Rizzieri, D. A.; Walter, R. B.; Spira, A. I.; Chung, K. Y.; Stock, W.; He, S.; Boni, J.; Atallah, E. |
| Abstract Title: | Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute leukemia |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419406295 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.2662.2662 |
| Notes: | Meeting Abstract: 2662 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
